Interestingly, Xing et al., (2004) [20] reported GAPDH as a target protein of the saframycin antiproliferative agents for leukaemia and tumour-derived cells, where it forms a ternary complex with saframycin-related compounds and DNA, inducing a toxic response in cells. The gene discussed is GAPDH; the disease is neoplasm.